Gland Pharma Limited has announced that it has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). The approved product is therapeutically equivalent to the reference listed drug, Pataday Once Daily Relief, 0.7%, manufactured by Alcon Laboratories Inc. This ophthalmic solution is indicated for the treatment of ocular itching associated with allergic conjunctivitis. Gland Pharma, established in 1978, is a pharmaceutical company focused on generic injectables and ophthalmics. It has a global presence in over 60 countries and a diverse product portfolio including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions.
